This review describes the microbiology, diagnosis and management of pericarditis due to anaerobic bacteria. The predominant anaerobes recovered from patients with pericarditis were: gram-negative bacilli (mostly of the Bacteroides fragilis group), anaerobic streptococci, Clostridium spp., Fusobacterium spp., and Bifidobacterium spp. Anaerobic bacteria can be isolated in pericarditis resulting from the following mechanisms: (1) spread from a contiguous focus of infection, either de novo or after surgery or trauma (pleuropulmonary, esophageal fistula or perforation, and odontogenic); (2) spread from a focus of infection within the heart, most commonly from endocarditis; (3) hematogenous infection, and (4) direct inoculation as a result of a penetrating injury or cardiothoracic surgery. No differences were found in the clinical diagnostic features between cases of pericarditis due to anaerobic bacteria and those due to aerobic and facultative bacteria. Anaerobic gram-negative bacilli have increased their resistance to penicillins and other antimicrobials in the last decade. Complete identification and testing for antimicrobial susceptibility and lactamase production are therefore essential for the management of infections caused by these bacteria. Treatment of pericarditis involving anaerobic bacteria includes the use of antibiotic therapy effective against these organisms.

Keywords:
Anaerobic bacteria, Pericarditis, Bacteroides fragilis, Peptostreptococcus sp., β-Lactamase
1.
Brook I: Indigenous microbial of humans; in Howard RJ, Simmons RL (eds): Surgical Infectious Diseases, ed 3. Norwalk, Appleton & Lange, 1995, pp 37–46.
2.
Boyle JD, Pearce ML, Guze LB: Purulent pericarditis: Review of literature and report of eleven cases. Medicine 1961;40:119–144.
3.
Gould K, Barnett JA, Sanford JP: Purulent pericarditis in the antibiotic era. Arch Intern Med 1974;134:923–927.
4.
Rubin RH, Moellering RC: Clinical microbiologic and therapeutic aspects of purulent pericarditis. Am J Med 1975;59:68–78.
5.
Klacsmann PG, Bulkley BH, Hutchins GM: The changed spectrum of purulent pericarditis. Am J Med 1975;59:68–78.
6.
Ilan Y, Oren R, Ben-Chetrit E: Acute pericarditis: Etiology, treatment and prognosis. Jpn Heart J 1991;32:315–321.
7.
Soler-Soler J, Permanyer-Miralda G, Sagrista-Sauleda J: A systematic diagnostic approach to primary acute pericardial disease: The Barcelona experience. Cardiol Clin 1990;8:609–620.
8.
Connolly DC, Burchell HB: Pericarditis: A 10-year survey. Am J Cardiol 1961;7:7–14.
9.
Brook I, Frazier EH: Microbiology of acute purulent pericarditis. A 12-year experience in a military hospital. Arch Intern Med 1996;156:1857–1860.
10.
Skiest DJ, Steiner D, Werner M, Gamer JG: Anaerobic pericarditis: Case report and review. Clin Infect Dis 1994;19:435–440.
11.
Aikat S, Ghaffari S: A review of pericardial diseases: Clinical, ECG and hemodynamic features and management. Cleve Clin J Med 2000;67:903–914.
12.
Hancock EW: Differential diagnosis of restrictive cardiomyopathy and constrictive pericarditis. Heart 2001;86:343–349.
13.
Fowler NO, Manitsas GT: Infectious pericarditis. Prog Cardiovasc Dis 1973;16:323–336.
14.
Corey GR, Campbell PT, Van Trigt P, Kenney RT, O’Connor CM, Sheikh KH, Kisslo JA, Wall TC: Etiology of large pericardial effusions. Am J Med 1993;95:209–213.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.